Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917556 | 1.00 | MAPT (0.55) | MAPTKMT2AMEN1NPSR1CTDSP1 | |
| SCHEMBL917257 | 0.87 | MAPT (0.53) | MAPTKMT2AMEN1NPSR1CTDSP1 | |
| SCHEMBL917258 | 0.87 | MAPT (0.53) | MAPTKMT2AMEN1NPSR1CTDSP1 | |
| SCHEMBL3849342 | 0.85 | ALDH1A1 (0.47) | MAPTKMT2AMEN1NPSR1CTDSP1 | |
| SCHEMBL29072525 | 0.82 | TTR (0.63) | MAPTKMT2AMEN1NPSR1ALDH1A1 | |
| SCHEMBL7031256 | 0.80 | MAPT (0.50) | MAPTKMT2AMEN1NPSR1CTDSP1 | |
| SCHEMBL917132 | 0.79 | TTR (0.70) | MAPTKMT2AMEN1NPSR1CTDSP1 | |
| SCHEMBL917134 | 0.79 | TTR (0.70) | MAPTKMT2AMEN1NPSR1CTDSP1 | |
| SCHEMBL6323811 | 0.77 | MAPT (0.72) | MAPTKMT2AMEN1NPSR1CTDSP1 | |
| SCHEMBL6323819 | 0.77 | MAPT (0.72) | MAPTKMT2AMEN1NPSR1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198313-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | KONKEL MICHAEL | 2011-07-21 | — | — | US | disclosed |
| US-7868034-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2011-01-11 | — | — | US | disclosed |
| EP-2241316-A1 | Indolone compounds useful to treat cognitive impairment | Helicon Therapeutics, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-1957067-B1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | HELICON THERAPEUTICS INC (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100179187-A1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-07-15 | — | — | US | disclosed |
| EP-2140864-A2 | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-2140862-A2 | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-7642281-B2 | Indolone compounds useful to treat cognitive impairment | HELICON THERAPEUTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2009-12-24 | — | — | US | disclosed |
| US-20070135509-A1 | Indolone compounds useful to treat cognitive impairment | BLACKBURN THOMAS P | 2007-06-14 | — | — | US | disclosed |
| US-20070135510-A1 | Indolone Compounds Useful To Treat Cognitive Impairment | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-06-14 | — | — | US | disclosed |
| US-7220775-B2 | Compound useful for the treatment of neuropathic pain | H. LUNDBECK A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| US-20070054910-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | KONKEL MICHAEL | 2007-03-08 | — | — | US | disclosed |
| US-7081470-B2 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S | 2006-07-25 | — | — | US | disclosed |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| US-20040102507-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (DK) | 2004-05-27 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | MAPT 3040/4885KMT2A 4393/4885MEN1 4213/4885 |
| US-20100179187-A1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | CHAT, AANAT, TPH2 | MAPT 100/4885KMT2A 1706/4885MEN1 3410/4885 |
| US-20070135509-A1 | Indolone compounds useful to treat cognitive impairment | CHAT, AANAT, TPH2 | MAPT 100/4885KMT2A 1706/4885MEN1 3410/4885 |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | MAPT 3040/4885KMT2A 4393/4885MEN1 4213/4885 |
| US-20110178125-A1 | USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | GALR3, GALR1, GALR2 | MAPT 2912/4885KMT2A 3812/4885MEN1 3562/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | MAPT 1723/4885KMT2A 3428/4885MEN1 3067/4885 |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | GALR3, GALR2, GALR1 | MAPT 3133/4885KMT2A 4104/4885MEN1 4030/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | MAPT 3177/4885KMT2A 4209/4885MEN1 4128/4885 |
| US-20070054910-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR1, GALR2 | MAPT 2912/4885KMT2A 3812/4885MEN1 3562/4885 |
| US-20070135510-A1 | Indolone Compounds Useful To Treat Cognitive Impairment | CHAT, AANAT, TPH2 | MAPT 100/4885KMT2A 1706/4885MEN1 3410/4885 |
| US-20040102507-A1 | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR1, GALR2 | MAPT 2912/4885KMT2A 3812/4885MEN1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.